Literature DB >> 10952223

The activity of class I and II alcohol dehydrogenase isoenzymes in the sera of patients with liver tumours.

L Chrostek1, M Szmitkowski.   

Abstract

We have measured the activity of class I and II alcohol dehydrogenase isoenzymes in the sera of patients with liver tumours, using class-specific fluorogenic naphthaldehydes as substrates. The activity of the tested isoenzymes was unchanged in primary tumours and significantly increased (class I) in metastatic liver tumours. The total enzyme activity was also increased (3-fold) in this group of patients. The elevated activity of class I isoenzymes in secondary tumours seems to be caused by the enzyme released from primary cells originating in the other organs, but increased total enzyme activity measured with chromogenic substrates may be proof of the presence of other classes of isoenzymes. These results show that the elevated class I isoenzymes and total enzyme activity in the sera of patients with liver tumours may indicate the metastatic origin of these tumours.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952223     DOI: 10.1515/CCLM.2000.059

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  3 in total

1.  Activity of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in the sera of patients with breast cancer.

Authors:  Wojciech Jelski; Lech Chrostek; Wlodzimierz Markiewicz; Maciej Szmitkowski
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

2.  Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with liver cancer.

Authors:  Wojciech Jelski; Bogdan Zalewski; Maciej Szmitkowski
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

3.  Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach.

Authors:  Faryal Mehwish Awan; Anam Naz; Ayesha Obaid; Amjad Ali; Jamil Ahmad; Sadia Anjum; Hussnain Ahmed Janjua
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.